EXAS
Exact Sciences Corp
Company · XNAS · US · USD
Market price
$103.44
+$0.115 (+0.11%) · 6 months
| Date and time | Price |
|---|---|
| Feb 9, 2026 | $103.32 |
| Feb 10, 2026 | $103.35 |
| Feb 11, 2026 | $103.43 |
| Feb 12, 2026 | $103.23 |
| Feb 13, 2026 | $103.24 |
| Feb 17, 2026 | $103.31 |
| Feb 18, 2026 | $103.36 |
| Feb 19, 2026 | $103.29 |
| Feb 20, 2026 | $103.43 |
| Feb 23, 2026 | $103.39 |
| Feb 24, 2026 | $103.45 |
| Feb 25, 2026 | $103.27 |
| Feb 26, 2026 | $103.25 |
| Feb 27, 2026 | $103.38 |
| Mar 2, 2026 | $103.35 |
| Mar 3, 2026 | $103.37 |
| Mar 4, 2026 | $103.50 |
| Mar 5, 2026 | $103.32 |
| Mar 6, 2026 | $103.50 |
| Mar 9, 2026 | $103.71 |
| Mar 10, 2026 | $103.37 |
| Mar 11, 2026 | $103.40 |
| Mar 12, 2026 | $103.27 |
| Mar 13, 2026 | $103.57 |
| Mar 16, 2026 | $103.85 |
| Mar 17, 2026 | $103.94 |
| Mar 18, 2026 | $103.75 |
| Mar 19, 2026 | $103.92 |
| Mar 20, 2026 | $104.91 |
| Aug 10, 2026 | $103.44 |
- Period change
- +0.11%
- Period low
- $103.23
- Period high
- $104.91
- Observations
- 30
- Updated
- Aug 10, 2026, 6:26 PM
About Exact Sciences Corp
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
Company websiteClassifications
- Biotechnology · Biotech
- Pharmaceuticals · Pharma
- Healthcare
Market details
- Type
- Company
- Market
- XNAS
- Operating market
- XNAS
- Country
- US
- Currency
- USD
- Market capitalization
- —
- Employees
- 7K